Cell News and Research

RSS

Survey analyses management of patients suffering from EGFRI toxicities

A recent survey of nurses from seven European countries, published in the peer-reviewed journal ecancermedicalscience, has analysed the management of patients suffering from toxicities due to treatment with epidermal growth factor receptor inhibitors.

14 Oct 2011

New dual drug combinations in development for various cancers

A rarely used—and as yet largely unproven—approach to drug development has emerged as a significant tool in the effort to create high-impact new cancer drugs.

14 Oct 2011

Merck announces results from ISENTRESS Phase III combination study on HIV-1

Merck, known as MSD outside the United States and Canada, today announced results of new exploratory pre-specified analyses from the ongoing STARTMRK Phase III study of its integrase inhibitor ISENTRESS (raltegravir) Tablets in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.

14 Oct 2011

Micromet receives FDA feedback on blinatumomab registration for R/R ALL

Micromet, Inc. today outlined a clinical development plan intended to support U.S. registration of its lead product candidate blinatumomab in patients with B-precursor relapsed/refractory (r/r) acute lymphoblastic leukemia.

14 Oct 2011

BCL11A protein might serve as potential target for sickle cell disease

Flipping a single molecular switch can reverse illness in a model of sickle cell disease, according to a study by researchers at Children's Hospital Boston and Dana-Farber Cancer Institute. When turned off, the switch, a protein called BCL11A, allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.

14 Oct 2011

Avita Medical introduces ReCell Spray-On Skin for chronic leg ulcers

Avita Medical Ltd., the regenerative medicine company, announced today that it has launched ReCell Spray-On Skin for the treatment of chronic leg ulcers, a market estimated at over US$1 billion.

14 Oct 2011

Scientisits uncover evidence of powerful new cancer genetic networks

In findings with major implications for the genetics of cancer and human health, researchers at Beth Israel Deaconess Medical Center (BIDMC) and two other science teams in New York City and Rome have uncovered evidence of powerful new genetic networks and showed how it may work to drive cancer and normal development.

14 Oct 2011

Manhattan Scientifics' nano-electromagnetic sensing technology can detect MRD in leukemia

Manhattan Scientifics announced today that the National Cancer Institute (NCI) has funded a grant for its Senior Scientific, LLC unit, for the use of its proprietary, highly precise magnetic cancer cell measurement in leukemia research for determining the progress of cancer treatment.

14 Oct 2011

EMBO, EMBC and Singapore sign cooperation agreement

Scientists in Singapore and Europe will have new avenues for scientific interaction, following a cooperation agreement between EMBO, its intergovernmental funding body, EMBC, and the government of Singapore.

14 Oct 2011

New insight into how emphysema and COPD develop

By studying mice exposed to tobacco smoke for a period of months, researchers have new insight into how emphysema and chronic obstructive pulmonary disease (COPD) develop.

14 Oct 2011

Cord blood stem cells can repair cardiac muscle after heart attack

At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient's own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart attack.

14 Oct 2011

Mathematical optimization models to improve radiation therapy for cancer

Engineering researchers at the University of Arkansas have developed mathematical optimization models that will make radiation treatment plans safer and more efficient than conventional plans.

From Elekta 14 Oct 2011

JCO publishes Keryx's KRX-0401 Phase 1 / 2 combination study on advanced MM

Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.

14 Oct 2011

Insight into how powerful anti-HIV antibody grabs hold of the virus

Researchers at The Scripps Research Institute have uncovered the surprising details of how a powerful anti-HIV antibody grabs hold of the virus. The findings, published in Science Express on October 13, 2011, highlight a major vulnerability of HIV and suggest a new target for vaccine development.

14 Oct 2011

BHI warns consumers about inherent risks linked with hearing devices

The Better Hearing Institute (BHI) is warning consumers of the inherent risks associated with purchasing over-the-counter, one-size-fits-all hearing aids instead of consulting a hearing healthcare professional.

14 Oct 2011

NIH awards Salk Institute $4.5M to establish new Neuroscience Core Center

The National Institutes of Health has announced that the Salk Institute will receive $4.5 million to establish a Neuroscience Core Center, a new research center intended to accelerate brain research that lays the foundation for developing new ways to treat congenital brain defects and neurological diseases.

14 Oct 2011

Potential new protein target for sickle cell disease

National Institutes of Health-funded scientists have corrected sickle cell disease in adult laboratory mice by activating production of a special blood component normally produced before, but not after, birth.

14 Oct 2011

Researchers control itch without dulling morphine's pain-killing effects

Itching is one of the most prevalent side effects of powerful, pain-killing drugs like morphine, oxycodone and other opioids. The opiate-associated itch is so common that even women who get epidurals for labor pain often complain of itching. For many years, scientists have scratched their own heads about why drugs that so effectively suppress pain also induce itch.

14 Oct 2011

Stopping necroptosis in keratinocytes prevents skin inflammation

The outer layer of the skin, called the epidermis, forms a critical physical and immunological wall that serves as the body's first line of defense against potentially harmful microorganisms. Most of the epidermis consists of cells called keratinocytes that build a mechanical barrier but also perform immune functions.

14 Oct 2011

Cylene advances preclinical development of CX-5461 for treatment of cancer

Cylene Pharmaceuticals, Inc. has advanced its targeted, non-genotoxic, activator of p53 for the treatment of leukemias, lymphomas and multiple myeloma through formal preclinical development, the Company announced today.

14 Oct 2011